Silo Wellness Inc signs distribution deal with Flawless CBD for functional mushroom products
February 2nd, 2022
Psychedelics, Top News
LONDON, Feb. 2, 2022 /PRNewswire/ — Silo Wellness Inc (CNSX: SILO) has signed a distribution deal with UK based Flawless CBD Distribution to distribute the Marley one Brand across the UK. The Marley one brand is a range of functional mushroom products, which are 100% natural and nonpsychedelic, created under the Bob Marley brand. “We have seen tremendous consumer interest in the Marley One brand, and we are pleased to announce a distribution partner for the all-important UK market,” said Douglas K. Gordon, Silo Wellness CEO.
Flawless CBD will distribute the Marley One mushroom line, beginning with the five functional mushroom tinctures, to retailers across the UK. The initial lineup includes five different tinctures, each with a unique health benefit:
- One Mind: A coffee-flavored blend of lion’s mane and gingko biloba designed to improve focus and cognitive function.
- One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function.
- One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion.
- One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health.
- One Rest: A vanilla-flavored blend of reishi and valerian root designed to help reduce tension and stress and improve quality of sleep.
“The wider goal is to remove the stigma of mushrooms (and marijuana) and to get people to look at these products without all the concerns from preconceived notions. We want to be able to educate our customers with the natural health benefits these products can have without the psychoactive and psychedelic element.” Irin Maini (from Flawless CBD) explains.
This coincides with the launch of the Bob Marley ‘One Love’ Experience Launching tonight at the famed Saatchi Gallery, in Chelsea. The Bob Marley One Love Experience will make its global debut this for a ten-week exhibition before embarking on a multi-city tour. The experience will showcase unseen Marley photographs and memorabilia whilst immersing its audiences on a journey through his lifestyle, passions, influences, and enduring legacy. Fans will be able to venture through the One Love Forest, visit the Soul Shakedown Studio and delve into the multi-sensory experience celebrating one of the world’s most beloved and unifying musical figures.
Flawless CBD is a leading distributor of CBD and health and wellness products across the UK, supplying over 5,000 retailers and e-stores in the UK and Europe. Given that the mushrooms are functional, they’re also legal to purchase everywhere. Customers will be able to purchase the Marley One tinctures online as well as through retailers across the country.
Contact: Callum Colley, 0116 234 4820
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.